Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

earn passive income by investing in dividend paying stocks
Dividend Stocks

Want Set-and-Forget Income? This 4% Yield TSX Stock Could Deliver in 2026

Emera looks like a “sleep-well” TFSA utility because its regulated growth plan supports a solid dividend, even after a big…

Read more »

A worker wears a hard hat outside a mining operation.
Stocks for Beginners

Mining Momentum: 2 TSX Stocks That Could Surprise Investors This January

Mining stocks could kick off 2026 with another surprise run as rate-cut hopes meet tight commodity supply.

Read more »

ETF is short for exchange traded fund, a popular investment choice for Canadians
Investing

A 10.4% High-Yield Income ETF That You Can Take to the Bank

Global X Equal Weight Canadian Bank Covered Call ETF (TSX:BKCC) stands out as an excellent sector covered-call ETF for 2026.

Read more »

canadian energy oil
Energy Stocks

Energy Loves a New Year: 2 TSX Dividend Stocks That Could Shine in January 2026

Cenovus and Whitecap can make January feel like “payday season,” but they only stay comforting if oil-driven cash flow keeps…

Read more »

man looks surprised at investment growth
Dividend Stocks

The Market’s Overlooking 2 Incredible Dividend Bargain Stocks

Sun Life Financial (TSX:SLF) stock and another dividend bargain are cheap.

Read more »

Confused person shrugging
Dividend Stocks

1 Simple TFSA Move Canadians Forget Every January (and it Costs Them)

Starting your TFSA early in January can add months of compounding and dividends you can’t get back.

Read more »

dividend stocks bring in passive income so investors can sit back and relax
Investing

Will Shopify’s Uptrend Continue in 2026?

Given its strong fundamentals and growth potential, I expect Shopify’s uptrend to continue this year.

Read more »

investor looks at volatility chart
Tech Stocks

1 Magnificent Canadian Tech Stock Down 38% to Buy and Hold for Decades

Constellation Software is a TSX tech stock that offers significant upside potential to shareholders over the next 12 months.

Read more »